Mechanism of Puromycin in inhibition of translation
Reading File
Finding Sources
Searching the Web
puromycin mechanism inhibition of translation ribosome aminoacyl-tRNA mimicry
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC7229235
Reading File
I now have comprehensive information from Harper's Biochemistry and the PMC review article. Here is the full detailed answer:
Mechanism of Puromycin in Inhibition of Translation
1. Origin and Nature
Puromycin is a naturally occurring aminonucleoside antibiotic produced by Streptomyces alboniger. It inhibits protein synthesis in both prokaryotes and eukaryotes, making it distinct from most antibiotics that target only bacterial (70S) ribosomes. - [Harper's Illustrated Biochemistry, 32nd Ed]
2. Structural Basis: Aminoacyl-tRNA Mimicry
The key to puromycin's mechanism lies in its structure:
- It resembles the 3' end of aminoacyl-tRNA (specifically tyrosyl-tRNA), consisting of a modified adenosine nucleoside covalently linked to a tyrosine amino acid.
- The critical structural difference: in genuine aa-tRNA the amino acid is attached to the ribose via a labile ester bond, whereas in puromycin it is linked via a stable, non-hydrolyzable amide (peptide) bond (see figure below).
This single chemical distinction is what makes puromycin a "dead-end" substrate for the ribosome.
3. Step-by-Step Mechanism
Step 1 - A-site Entry
During normal translation elongation, an aminoacyl-tRNA enters the ribosomal A site (acceptor site), guided by EF-Tu (in prokaryotes) or eEF-1A (in eukaryotes) and GTP hydrolysis. Puromycin bypasses this requirement - it can enter the A site independently, without needing an elongation factor or GTP, because it already structurally resembles the aa end of aa-tRNA.
Step 2 - Peptidyl Transfer
The peptidyltransferase center (PTC) in the 23S/28S rRNA of the large ribosomal subunit catalyzes a nucleophilic attack by the free α-amino group of puromycin on the ester bond linking the nascent polypeptide chain to the P-site peptidyl-tRNA. This is chemically identical to a normal peptide bond formation reaction. The result: the entire nascent polypeptide chain is transferred onto puromycin, forming a peptidyl-puromycin adduct.
Step 3 - Premature Termination (Irreversible)
Unlike a normal aa-tRNA, the peptidyl-puromycin adduct cannot undergo translocation normally, and critically, its amide bond cannot be cleaved by an incoming aa-tRNA in the next elongation cycle. There is no 3'-OH available for continued chain elongation. The peptidyl-puromycin adduct spontaneously dissociates from the ribosome, releasing a truncated, non-functional polypeptide with puromycin covalently attached to its C-terminus.
Step 4 - Ribosome Disassembly
After peptidyl-puromycin release, the 80S (or 70S) ribosome disassembles into its large and small subunits. This disassembly is energy-independent. The ribosome falls off the mRNA as a 70S/80S particle rather than in the dissociated form that occurs during physiological termination - this is different from normal termination. [Mechanism of Puromycin Action, PNAS 1973]
4. Summary Table
| Feature | Normal aa-tRNA | Puromycin |
|---|---|---|
| Enters A site? | Yes (EF-Tu/GTP-dependent) | Yes (spontaneous, energy-independent) |
| Free α-amino group? | Yes | Yes |
| Accepts peptide chain from P site? | Yes | Yes |
| Bond to amino acid | Labile ester (cleavable) | Stable amide (non-cleavable) |
| Can be translocated? | Yes | Poorly/No |
| Elongation can continue? | Yes | No - chain terminated |
| Product released? | Stays in ribosome | Peptidyl-puromycin released |
5. Fate of the Truncated Polypeptide
The released peptidyl-puromycin products are truncated at random positions across all actively translating polypeptides. These aberrant proteins are rapidly recognized by cellular quality control machinery and targeted for proteasomal degradation. This ensures that truncated, potentially toxic proteins do not accumulate. The Aviner 2020 review in Seminars in Cell & Developmental Biology describes this degradation pathway in detail.
6. Why It Affects Both Prokaryotes and Eukaryotes
Unlike tetracyclines or aminoglycosides (which target the 30S subunit) or chloramphenicol (which targets 70S PTC specifically), puromycin's structural mimicry of aa-tRNA is recognized by the universally conserved peptidyltransferase center (PTC) present in ribosomes from all domains of life. This is why it lacks clinical utility as an antibiotic - it is toxic to host cells - but is widely used as:
- A selectable marker in transfected mammalian cell lines (cells expressing puromycin N-acetyltransferase resist it)
- A research tool to study translation kinetics and visualize nascent protein synthesis (SUnSET assay, anti-puromycin immunofluorescence)
7. Contrast With Cycloheximide
- Cycloheximide inhibits the peptidyltransferase of the 60S subunit in eukaryotes, blocking translocation.
- Puromycin mimics aa-tRNA and causes premature chain release - it is a substrate of the PTC, not a blocker.
- Harper's notes that cycloheximide can limit puromycylation by blocking A-site availability, while emetine can enhance it. - [Harper's Illustrated Biochemistry, 32nd Ed]
In brief: Puromycin acts as a structural mimic of aminoacyl-tRNA at the 3' end. It enters the ribosomal A site, accepts the growing peptide chain via peptidyltransferase (forming a stable amide bond), and then dissociates as a peptidyl-puromycin adduct that cannot be extended. This causes premature, irreversible termination of translation and ribosome disassembly.
This is a shared conversation. Sign in to Orris to start your own chat.